AGC Biologics is partnering with Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin. The companies will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Molecular Partners plans to initiate clinical studies for this program in 2H20.
AGC Biologics will manufacture at 100 liter and 1,000 liter scales, which is suitable for development and initial global supply for patients in need. Based upon preliminary data, a subcutaneous administration of MP0420 could function as both a therapeutic for existing viral infection and as a potential preventive therapy.
"Securing manufacturing capacity is a critical step in advancing our novel antiviral DARPin program to clinical readiness. We are highly committed to move to patients as rapidly as possible, building upon our strong preclinical data that shows potential best in class potency in neutralizing live virus," says Patrick Amstutz, CEO of Molecular Partners. "We are greatly encouraged by the recent data supporting the potential of our unique tri-specific approach to target SARS-CoV-2, as we believe novel therapeutics will be an essential tool for addressing the global COVID-19 pandemic."
AGC Biologics has manufacturing facilities in Seattle, WA; Boulder, CO; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan, that provide manufacturing, including commercial market supplies with FDA, PDMA and EMA approvals. These services have been focused on proteins as Drug Substance, like antibody fragments, enzymes, vaccines and much more, as well as plasmid DNA.